news
First long-acting HIV treatment approved in Europe
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
List view / Grid view
HIV (Human Immunodeficiency Virus)
news
Noncommunicable diseases are leading cause of death and disability worldwide, says WHO
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.
news
Trial of new HIV PrEP medication stopped early due to effectiveness
The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.
news
EIB to support COVID-19 therapy with €24.5 million investment
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
news
Study suggests dolutegravir is the optimal first-line HIV medication
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
news
Dolutegravir plus lamivudine shows non-inferior HIV-1 suppression in Phase III trials
Dolutegravir plus lamivudine was as effective at suppressing HIV-1 in adult trial participants as a three-drug regimen, dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
article
Developing a preventive vaccine regimen to tackle Ebola
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
news
Long-acting injectable HIV PrEP outperforms commercially available daily pill
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
news
Gilead files lawsuit against US federal government over alleged contract breaches
Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
news
Positive results from initial lopinavir-ritonavir COVID-19 clinical trial
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
news
New HIV PrEP drug could derail efforts to expand virus prevention coverage
US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.
news
Regulatory submissions made for dispersible formulation of dolutegravir
ViiV Healthcare has filed submissions to the FDA and EMA for the first dispersible formulation of dolutegravir (DTG) for children living with HIV.
news
Once-per-month HIV drugs could soon be available
According to a recent article, drug companies are developing longer-acting, injectable HIV treatments.
news
Weekly injections shows HIV-1 viral suppression
Results from a pivotal trial of a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic for previously treated HIV-1 infected patients...
news
Trogarzo approved for HIV patients with limited treatment options
The FDA has approved Trogarzo for adult patients whose HIV infections cannot be successfully treated...
